Myriad Genetics, Inc. (MYGN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Myriad Genetics, Inc. (MYGN)

MYGN 6.565

-3.2%

Dec 23 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: bob zagorin	6/15/2011 12:53:21 PM
	of 2355

Auriga Downgrades Myriad Genetics (MYGN) to Hold on Valuation; Delayed Gratification Auriga downgraded Myriad Genetics (NASDAQ: MYGN) to Hold. PT lowered from $27 to $25. Auriga analyst says, "Myriad Genetics has done a good job navigating the weak diagnostics market, posting 11% growth in FY10 and appears on-track to post 10% growth in FY11. Further, MYGN has been making the right investments both internally (via increased RD and geographic expansion) and externally (via small tuck-in deals). Finally, management has put excess cash to work repurchasing over $250MM worth of shares. Investors have responded positively and shares have appreciated 6% YTD versus the SP500's 3%. While we continue to like MYGN's steady business mix, emerging product pipeline and support its plans to increase clinical activity, the current valuation pushes us to the sidelines."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next